<DOC>
	<DOCNO>NCT02298179</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity two dose investigational RSV F subunit vaccine administer intramuscularly ( IM ) . In current Phase 1 , first-in-human study , three different antigen amount select evaluated stepwise manner three different cohort ( cohort 1 : low dosage RSV F subunit vaccine , cohort 2 : middle dosage RSV F subunit vaccine , cohort 3 : high dosage RSV F subunit vaccine ) . In addition , effect adjuvant , either aluminum hydroxide MF59 , antibody kinetics post-vaccination different time point evaluate compare unadjuvanted RSV F subunit vaccine dosage level</brief_summary>
	<brief_title>To Evaluate Safety Ability Medicine Induce Antibodies Against Respiratory Syncytial Virus Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>MF59 oil emulsion</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Healthy male nonpregnant female 18 45 year age time enrollment . 1 . Individuals severe chronic acute disease . 2 . Individuals history illness ongoing illness may pose additional risk subject he/she participate study , include follow : History chronic respiratory illness , include current diagnosis asthma within 2 year , exercise induce wheezing , reactive airway disease , emphysema , chronic bronchitis , cystic fibrosis chronic obstructive pulmonary disease ( COPD ) . Any respiratory illness within 7 day prior receive first study vaccination . Any active pulmonary infection inflammatory condition , even absence febrile episode , within 14 day prior first study vaccination . Hepatitis B hepatitis C infection . 3 . Individuals participate clinical trial another investigational product 28 day prior receive first study vaccination intent participate another clinical study time conduct study . 4 . Individuals receive vaccine 28 day prior enrollment study , plan receive nonstudy vaccine within 28 day second dose study vaccine . 5 . If female , 'of childbearing potential ' , sexually active use 'acceptable contraceptive method ' least two month prior study entry . 6 . If female subject childbearing potential positive urine pregnancy test prior study injection , currently lactate . 7 . If female childbearing potential sexually active , refusal use 'acceptable contraceptive method ' three week last study vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>